This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DETROIT, March 20, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp
. (OTCQB:CTLE) is pleased to report that Dr. Victor Castano, Chief Innovations Officer of Nano Labs, presented "A nanotechnology approach to immunology: challenges and opportunities." at the Target Meeting ("TM") 2nd World Immunology Online Conference.
The TM 2nd World Immunology Online Conference, held March 19-21, 2013, included sixty (60) international speakers over the three (3) day conference, providing speakers and attendees with in-depth discussion, collaboration and networking.
Dr. Castano's presentation included a historical review of how nanostructures, both natural and man-made, have played important roles in immunology, emphasizing the challenges and advantages that are present through novel nanoscale approaches.
Dr. Castano further presented a number of Nano Labs' projects currently underway, including using state-of-the art technologies, such as MEMS and NEMS, for immunological applications, discussing the potential limitations and challenges that such techniques pose for the practicing immunologists. (For further reading, please refer to Nano Labs' press release of March 4, 2013, entitled "Nano Labs Develops Diagnostic Technology to Identify Tuberculosis (TB) Through Novel Nanotechnologies. Researchers Present Industry With Promising Diagnostic Test Results Identifying TB Through Nano Biosensors".)
"The online conference was a great success. You have to appreciate how so many internally recognized experts can come together in an innovative and informative fashion, all without the travel and expense, to collaborate and exchange ideas," stated Dr. Castano. "Our tuberculosis detector was very well received and attracted a lot of attention from American and European organizations interested in continuing discussions. There are many remarkable and major developments happening in the life sciences sector that are game changing right now and we look forward to being a part of that."
About Target Meeting and the 2nd World Immunology Online Conference
Target Meeting is a leading online life science conference organizer developing many specialized conferences, seminars, and workshops to meet researcher's specific needs and requirements around the world. It will bring together leading professors, researchers, and life science suppliers worldwide to discuss the latest discovery of biomedical research. Through our well-organized conferences, seminars, or workshops, we have already built a good reputation in the field of life science. Target Meeting provides outstanding opportunities for scientists to share latest research, to inspire breakthrough ideas, and to establish and maintenance academic relationships through extensive interactions. For more information please visit
About Nano Labs
Nano Labs Corp. (CTLE) is a nanotechnology company which began during October 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. The Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit
The Nano Labs Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16293Forward looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.